|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone. | Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M | 2013 | 中国神经肿瘤杂志2013，11，1： | 8 |
| 2 | The nature of adolescent competencies predicted by preschool delay of gratification显示文摘 | MISCHEL W SHODA Y PEAKE P K | 1998 | Journal of Personality and social Psychology1998，，54： | 1 |
| 3 | Beyond dejot vu in the search for cross-situational consistency 显示文摘 | Mischel W & Peake P K | 1982 | Psychological Re- view1982，89，6： | 1 |
| 4 | Molecular pathology in adult high-grade gliomas:from molecular diagnostics to target therapies显示文摘 | Masui K Cloughesy T F Mischel P S | 2012 | Neuropathol Appl Neurobiol2012，38，3： | 1 |
| 5 | Targeting SREBP- 1-driven lipid metabolism to treat cancer 显示文摘 | GUO D L BELL E H MISCHEL P | 2014 | Curr Pharm Des2014，20，15： | 1 |
| 6 | Arteriovenous malformation animal model for radiosurgery: the rete mirabile显示文摘 | de Salles AA Solberg TD Mischel P | 1996 | AJNR Am J Neuroradiol1996，17，8： | 1 |
| 7 | Targeting SREBP - 1 - driven lipid metabolism to treat cancer显示文摘 | Guo D Bell EH Mischel P | 2014 | Curt Pharm Des2014，20，15： | 1 |
| 8 | Strategic Attention Deployment for Delay of Gratification in Working and Waiting Situations显示文摘 | PEAKE P K HEBL M MISCHEL W | 2002 | Developmental Psychology2002，38，2： | 1 |
| 9 | Arteriovenous malformation animal model for radiosurgery:the rete mirabile显示文摘 | De Salles AA Solberg TD Mischel P | 1996 | AJNR1996，17，： | 1 |
| 10 | Arteriovenous malformation animal model for radiosurgery:the fete mirabile 显示文摘 | De Salles AA Solberg TD Mischel P | 1996 | AJNR1996，17，： | 1 |
| 11 | Selective enhancement of glutamate-mediated pressor reponses after GABA(A)receptorblockade in the RVLM of sedentary versus soontaneouswheel running rats显示文摘 | Mueller P J Mischel N A | 2012 | Front Physiol2012，3，12： | 1 |
| 12 | Predcting AdolescentCognitive and Self-Regulatory Competencies from PreschoolDelay of Gratification:Identifying Diagnostic Conditions显示文摘 | Shoda Y Mischel W Peake P K | 1990 | Developmental Psychology1990，，26： | 1 |
| 13 | Tissue and cell-type specific expression of the tuberous sclerosis gene,TSC2,in human tissues显示文摘 | EMELIN J K MISCHEL P S | 1996 | Mod Pathol1996，9，： | 1 |
| 14 | Targeted molecular therapy of GBM 显示文摘 | Mischel P S Cloughesy T F | 2003 | Brain Pathol2003，13，1： | 1 |
| 15 | A pilot study of everolinms and gefitinib in the treatment of recurrent glioblastoma (GBM) 显示文摘 | KREISL T N LASSMAN A B MISCHEL P S | 2009 | J Neurooncol2009，92，1： | 1 |
| 16 | Neuropathology 显示文摘 | Mischel P S Vinters H V | 1995 | Neurosurg Clin N Am1995，6，3： | 1 |
| 17 | Glioblastoma: from molecular pathology to targeted treatment 显示文摘 | CLOUGHESY T F CAVENEE W K MISCHEL P S | 2014 | Annu Rev Patho12014，9，： | 1 |
| 18 | PTEN-mediated re- sistance to epidermal growth factor receptor kinase inhibitors 显示文摘 | Mellinghoff I K Cloughesy T F Mischel P S | 2007 | Clin Cancer Res2007，13，21： | 1 |
| 19 | PTEN mediated resistance to epidermal growth factor receptor kinase in hibitors显示文摘 | Mellinghoff I K Clouchesy T F Mischel P S | 2007 | Clin Cancer Res2007，13，21： | 1 |
| 20 | Arteriovenous malformation animal model for radiosurgery:the rete mirabile显示文摘 | De Salles AA Solberg TD Mischel P | 1996 | AJNR Am J Neuroradiol1996，17，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员